Project Grant R01HL175391
Award Date
6/15/24
Completion Date
5/31/28
Dollars Obligated
$566K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Albany, NY 12222, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,454,955 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Beckman Research Institute of the City of Hope. The grant titled "INTEGRATIVE ROLE OF RPS6KB1 IN PATHOLOGICAL CARDIAC REMODELING" aims to characterize the role of the RPS6KB1 protein in adaptive cardiac hypertrophy and heart failure progression, with a focus on understanding the regulation of RPS6KB1 through phosphorylation and...
This $1,660,873 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of the enzyme 15-PGDH in cardiac fibrosis and heart failure. The research aims to investigate how inhibiting 15-PGDH can suppress the activation of cardiac fibroblasts and prevent or reverse pathological cardiac fibrosis, a key contributor to diastolic dysfunction and heart failure with preserved ejection...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $244,589.00 to investigate the role of the VPS34 protein in the development of pulmonary arterial hypertension (PAH). The research aims to examine the regulation and mechanisms of VPS34 activation in PAH, determine the impact of VPS34 on proliferation and survival of pulmonary artery vascular smooth muscle cells, and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $732,779 to the University of Arizona to study the role of the serine-threonine kinase SGK1 in cardiometabolic heart failure with preserved ejection fraction (CMET HFPEF). The research aims to determine how cardiac-specific SGK1 regulates heart function, metabolism, and...
This federal Project Grant award of $748,829 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to explore the connection between a compromised "metabolic resuscitation system" and the pathogenesis of heart failure. The overarching objective is to determine how this novel system relates to the progression of heart failure and evaluate its potential as a therapeutic target and biomarker for...
This $121,773 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the cytosolic kinase SGK1 in driving pathological cardiac hypertrophy, and whether modulating its degradation via non-canonical ER-associated degradation (ERAD) can mitigate this condition. The research aims to 1) determine the effects of depleting endogenous SGK1 on cardiac myocyte...
This $1,088,500 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports three independent research projects related to genetic and molecular mechanisms of heart disease. Project #1 aims to define microRNA targeting events and their biological relevance in the heart, as well as understand the clinical significance of genetic variants that alter cardiovascular microRNA functions. Project #2 seeks to...
This $596,809.00 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to target the mitochondrial protein MitoNEET to address pulmonary hypertension (PH) secondary to lung disease (Group 3 PH). The research team at Emory University will conduct in vitro and in vivo studies to define how MitoNEET regulates pulmonary artery smooth muscle cell (PASMC) mitochondrial function and proliferation, as well...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to identify novel genes and biological mechanisms involved in heart failure (HF). The $817,208 award to the Broad Institute, Inc. will leverage high-throughput functional genomic assays, including cell painting and perturb-seq, to systematically analyze the impact of HF-associated genetic variants on cardiomyocyte phenotypes....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $732,119 to Temple University to investigate the role of the vascular pyruvate kinase M2 (PKM2) enzyme in mediating hypertension and vascular remodeling. The research aims to elucidate how PKM2 activation in vascular smooth muscle cells, through both metabolic and non-metabolic effects, contributes to hypertension and associated...